A peptidoform is one specific molecular form of the peptide — its sequence plus the modifications at given positions (HUPO-PSI term). This view preserves the reported terminal groups, residue modifications, and stereo markers from the source notation.

6-[(2S,3R,4R,6E)-3-Hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid]cyclosporin A

Identity summarySpecific molecular form represented

Identity status: Specific molecular form represented
Residues: 2
Peptidoform features: 2
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0039003	—	4	—	1	4

Residue view

Residue display

2 residues

X1X2

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

Non-standard residue tokenpos 1

Reported token 6 is not one of the 20 standard residue symbols in this display.

Non-standard residue tokenpos 2

Reported token cyclosporin A is not one of the 20 standard residue symbols in this display.

Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

XX

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached

3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

6 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Physicochemical descriptors unavailable

These descriptors require a standard parent-residue sequence. The module remains visible so modified or unresolved identities are not forced into unreliable computed values.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Structure-derived (developability)

Computed from the representative peptidoform's chemical structure. Rule-of-5 / beyond-Ro5 framing per Lipinski/Doak.

Topological polar surface area

278.8 Å²

Computed logP (Crippen)

3.44

Computed logP — distinct from the measured logD endpoint.

Hydrogen-bond donors

Hydrogen-bond acceptors

Rotatable bonds

Rule-of-5 / beyond-Ro5 flags

Beyond bRo5

2 Ro5 violations · MW 1,214.65 Da

Exposure / Absorption

1 records

What evidence describes systemic exposure or absorption?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeTmax

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Tmax1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	5400 seconds	Eligible when experimental context matches	human	Result: Reported point value · Molecular form: ATLPF0039003 · Route: oral · Source: Primary reference linked	Reference

Distribution / Barrier

2 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopePlasma protein binding Vd

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	2154 L	Eligible when experimental context matches	human	Result: Reported point value · Molecular form: ATLPF0039003 · Route: oral · Source: Primary reference linked	Reference

Plasma protein binding1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	97 %	Eligible when experimental context matches	human	Result: Reported point value · Molecular form: ATLPF0039003 · Route: oral · Source: Primary reference linked	Reference

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Excretion / Persistence

1 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeClearance

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	63.6 L/h	Eligible when experimental context matches	human	Result: Reported point value · Molecular form: ATLPF0039003 · Route: oral · Source: Primary reference linked	Reference

Evidence landscape

4 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

1 evidence record

Distribution / Barrier

2 evidence records

Metabolic & Proteolytic Stability

0 evidence records

Excretion / Persistence

1 evidence record

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Clearance

Plasma Protein Binding

Time To Max Concentration

Volume Of Distribution

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReference

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Excretion / Persistence Persistence	Clearance	63.6 L/h	Reported point value	Eligible when experimental context matches	human	Route: oral	Reference Primary reference linked
2	Distribution / Barrier Distribution	Plasma Protein Binding	97 %	Reported point value	Eligible when experimental context matches	human	Route: oral	Reference Primary reference linked
3	Exposure / Absorption Exposure	Time To Max Concentration	5,400 seconds	Reported point value	Eligible when experimental context matches	human	Route: oral	Reference Primary reference linked
4	Distribution / Barrier Distribution	Volume Of Distribution	2,154 L	Reported point value	Eligible when experimental context matches	human	Route: oral	Reference Primary reference linked

1–4 / 4

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

Summary1 linked product

Linked products: 1
Label context: None
Clinical trials: 25
Safety label cues: None

Linked products1 shown

Voclosporin

Peptide-product match

Reviewed peptide match

Route / product class

oral · Capsule

Clinical context

25 trial records · 18 exact intervention matches · 10 with results · latest 2026-02-10

Label safety context

No label safety cue linked

View product

Identity & reference map

4 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary1 reference group

Identity type: reported modified sequence
Reported notation: 0
Reference groups: 1
Measurements: 4
ATL peptide ID: ATLPC0035864

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 4

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 4

Different notation

Reported notation does not resolve to the current display sequence.

0 / 4

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

4 / 4

Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity

6-[(2S,3R,4R,6E)-3-Hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid]cyclosporin A

Reported names

No distinct human-readable aliases are exposed.

Reference map1 reference group

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	DistributionExposurePersistence Clearance, Plasma Protein Binding, Time To Max Concentration, Volume Of Distribution	No reported alias	4 identity 4 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0035864
Identity type: reported modified sequence
ADMET endpoints: 4
Evidence records: 4
Reference groups: 1
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0035864

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0035864' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0039003

—

Value

Analysis use

Assay / model

Result context

Reference

5400 seconds

Eligible when experimental context matches

human

Result: Reported point value · Molecular form: ATLPF0039003 · Route: oral · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

2154 L

Eligible when experimental context matches

human

Result: Reported point value · Molecular form: ATLPF0039003 · Route: oral · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

97 %

Eligible when experimental context matches

human

Result: Reported point value · Molecular form: ATLPF0039003 · Route: oral · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

63.6 L/h

Eligible when experimental context matches

human

Result: Reported point value · Molecular form: ATLPF0039003 · Route: oral · Source: Primary reference linked

Reference

ADMET domain

Endpoint

Reported value

Result type

Analysis use

Assay / model

Condition

Reference

Excretion / Persistence

Persistence

Clearance

63.6 L/h

Reported point value

Eligible when experimental context matches

human

Route: oral

Reference

Primary reference linked

Distribution / Barrier

Distribution

Plasma Protein Binding

97 %

Reported point value

Eligible when experimental context matches

human

Route: oral

Reference

Primary reference linked

Exposure / Absorption

Exposure

Time To Max Concentration

5,400 seconds

Reported point value

Eligible when experimental context matches

human

Route: oral

Reference

Primary reference linked

Distribution / Barrier

Distribution

Volume Of Distribution

2,154 L

Reported point value

Eligible when experimental context matches

human

Route: oral

Reference

Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

DistributionExposurePersistence

Clearance, Plasma Protein Binding, Time To Max Concentration, Volume Of Distribution

No reported alias

4 identity

4 evidence